Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of pembrolizumab plus neoadjuvant chemotherapy and adjuvant endocrine therapy in high-risk early ER-positive/HER2-negative breast cancer
MOH_2018-08-29_002461Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pembrolizumab + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoints: Safety, Antitumor activity and 3 more. Started Jun 2018; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2018-08-29_002461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-29_002461.